Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy

Strong Results But Merck & Co’s Keytruda Also Competing

 
• By Andrew McConaghie
  
new gsk logo and hq
GSK needs its own PD1/L1 therapy 'backbone' on which to build future cancer therapy combinations. • Source: GSK
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip